Back

Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Management of comorbidities and outcomes in atrial fibrillation (1) Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Goncalo Costa

Coimbra Hospital and University Center, Coimbra (Portugal)

7 More presentations in this session

Presentation thumbnail
Insights into type 2 diabetes mellitus in atrial fibrillation patients: a proteomics approach
Miss N. Atzemian (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Inflammation and long-term outcomes after first-time direct current cardioversion for atrial fibrillation: a nationwide register study
Doctor A. Langhoff (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial aibrillation: a report from 2 prospective observational registries
Doctor J. Imberti (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Risk of embolic events in patients with Chagasic Cardiomyopathy and Atrial Fibrillation despite antithrombotic therapy: is anticoagulation enough?
Doctor L. Echeverria (Floridablanca, CO)
Abstract Slides
Presentation thumbnail
Treated obstructive sleep apnoea and incident arrhythmias
Doctor H. He (Coventry, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Management of comorbidities and outcomes in atrial fibrillation (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Semaglutide improves contractile function in isolated human atrium
thumbnail
Congress Presentation
Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial
thumbnail
Congress Presentation
Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources